Annual return of 118.79% - See How Click here now!
TheWallStreetLeader.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to chat LIVE about these stocks and more on their upgraded website with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact Stock Profiler.US, LLC at (603) 424-4420.
-------------------------------------------
Airspan Networks Inc. (NASDAQ: AIRN | Quote | Chart | News | PowerRating) closed at $0.34 Tuesday, trading 60,600 shares.
Company News- September 30, 2008: One Communications Kenya Selects Airspan's WiMAX Infrastructure
Airspan Networks Inc. (NASDAQ: AIRN), a leading provider of WiMAX-based broadband wireless access networks, announced yesterday that it has been selected by One Communications (OneCom), a newly-acquired subsidiary of Safaricom, as their WiMAX infrastructure partner in OneCom's roll out of a nationwide WiMAX network across Kenya.
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About OneCom
OneCom was incorporated in 2006, and its subsidiaries provide various data communication services in Nairobi, Kenya. Safaricom acquired a 51 percent stake in the company in August following implementation of Kenya's unified licensing regime.
About Airspan Networks Inc.
Airspan is the industry's leading WiMAX pure player, ranked #1 for IEEE802.16-2004 WiMAX revenue in 2007 and has now been selected for some of the world's largest mobile WiMAX deployments. With direct sales offices throughout Asia, EMEA and the Americas, a worldwide network of resellers and agents, and partnership alliances with major OEMs, Airspan boasts over 100 commercial WiMAX deployments worldwide. www.airspan.com.
-------------------------------------------
Amgen Inc., (NASDAQ: AMGN | Quote | Chart | News | PowerRating) closed at $59.27 Tuesday, trading 14,370,400 shares.
Company News- September 30, 2008: Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology
Yesterday Amgen Inc., (NASDAQ: AMGN | Quote | Chart | News | PowerRating) announced it has received a summary of preliminary results from the Cochrane Collaboration's independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen has submitted the executive summary to regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).
To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol.
About The Cochrane Collaboration
The Cochrane Collaboration is an international not-for-profit and independent organization, dedicated to making up-to-date, accurate information about the effects of healthcare readily available worldwide. It produces and disseminates systematic reviews of healthcare interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. TheWallStreetLeader.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.businessnetwire.us, www.financialbusinessnews.us, www.fastmoneytalk.com, www.markettelegraph.com, www.associatesfortune.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage
CONTACT: Thewallstreetleader.com Tel: +1 603 424 4420 e-mail: info@ stockprofiler.us WWW: http://www.thewallstreetleader.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
